"Genentech is an incredibly rich scientific environment, and it has been very exciting for our group to collaborate on projects across all therapeutic areas and platforms. Our lead-finding efforts continue to advance for both small molecule and biologics efforts, and our scientists enjoy having the opportunity to make diverse contributions throughout the lifetime of a project, from inception to clinical candidate nomination."
I joined Genentech in January 2006 to head up the Biochemical Pharmacology group in the Small Molecules Division. We put in tremendous effort to build our Small Molecule Discovery effort to be a world-class platform. We have now combined our Small Molecule in vitro biology group with the Therapeutic Antibody in vitro group, to form one large group that provides quantitative in vitro support for all of Genentech’s therapeutic programs. This allows our scientists to focus on the underlying science behind diseases, independent of the drug discovery platform. Moreover, it allows our scientists to broaden their drug discovery expertise if they desire.
The scientists in our Therapeutic Antibody group develop quantitative bioanalytical assays to support antibody screening and characterization, including mechanistic, pharmacokinetic, and pharmacodynamic assessments. Our Small Molecule division has responsibility for Compound Management, ultra-high-throughput screening, fragment screening, and all of the biochemical and cellular assays that provide quantitative structure-activity relationship data to guide Medicinal Chemistry efforts. In both groups, we collaborate closely with the scientists in the Disease Biology groups to ensure the testing cascades used by teams are of high quality and provide the necessary detailed mechanistic data to ensure that the right molecules move into the clinic. It has been a tremendously gratifying opportunity to help build this department, and I'm excited by some of the tremendous talent we have attracted to our organization.
Journal of Medicinal Chemistry. 2013; 56(11):4597-610.
My research interests are broad given our focus on multiple therapeutic areas in support of the Therapeutic Antibody and Small Molecule pipeline. In addition to running a Project Leader Forum that serves to educate our Small Molecule leaders, we recently held a multi-year Therapeutic Antibody Educational Forum. We also support ongoing efforts to blend small molecule and large molecule drug discovery strategies and bring new technologies and biologics platforms to bear. We believe that exploring the pharmacology of these drugs, and delving into their mechanism of action, will ultimately benefit their therapeutic potential to patients’ lives.